DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Quisinostat
Quisinostat
An Overview of the Role of Hdacs in Cancer Immunotherapy
Histone Deacetylase Inhibitors Synergizes with Catalytic Inhibitors of EZH2 to Exhibit Anti-Tumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Design and Synthesis of Novel Classes of Hdacs and Kmts Inhibitors
Histone Deacetylase Inhibitors: a Prospect in Drug Discovery Histon Deasetilaz İnhibitörleri: İlaç Keşfinde Bir Aday
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Mechanisms and Clinical Significance of Histone Deacetylase Inhibitors: Epigenetic Glioblastoma Therapy
HHS Public Access Author Manuscript
Hippo Signaling Dysfunction Induces Cancer Cell Addiction to YAP
Histone Deacetylase Inhibitors As Anticancer Drugs
Preclinical Assessment of Histone Deacetylase Inhibitor Quisinostat As a Therapeutic Agent Against Esophageal Squamous Cell Carcinoma
An Overview of Epigenetic Agents and Natural Nutrition Products Targeting
Improving Drug Discovery Using Image-Based Multiparametric Analysis of Epigenetic Landscape
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
Targeting Histone Deacetylases with Natural and Synthetic Agents: an Emerging Anticancer Strategy
Ncomms9648.Pdf
Nanoparticle Formulations of Histone Deacetylase Inhibitors for Effective Chemoradiotherapy in Solid Tumors
Fabrication and Characterization of Panobinostat Loaded PLA-PEG Nanoparticles
Epigenetic Treatment of Solid Tumours: a Review of Clinical Trials Clara Nervi, Elisabetta De Marinis and Giovanni Codacci-Pisanelli*
Top View
New and Emerging HDAC Inhibitors for Cancer Treatment
JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
High-Throughput Identification of Post-Transcriptional Utrophin Up
The Application of Histone Deacetylases Inhibitors In
Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI Saumya S
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers
(Mesenchymal) Stem Cells
The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence MARILITA M
( 12 ) Patent Application Publication
Identification and Characterization of AES-135, a Hydroxamic Acid-Based
Β-Cyclodextrin-Poly (Β-Amino Ester) Nanoparticles Are a Generalizable Strategy for High Loading and Sustained Release Of
A High-Throughput Screening Identifies Histone Deacetylase Inhibitors As
Drug Repurposing Compound Library Plus (96-Well)
In Vivo Treatment with Epigenetic Modulating Agents Induces Transcriptional Alterations Associated with Prognosis and Immunomodulation in Multiple Myeloma
HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma
WO 2016/069854 Al 6 May 2016 (06.05.2016) P O P C T
(12) United States Patent (10) Patent No.: US 9,682,093 B2 Singh (45) Date of Patent: Jun
Histone Deacetylase Inhibitor Quisinostat Activates Caspase Signaling and Upregulates P53 Acetylation to Inhibit the Proliferation of Hepg2 Cells
International Application Number: PCT/US20 19/035464 (22)
The HDAC Inhibitor Quisinostat
Histone Deacetylase Inhibitors: Recent Outcomes from Clinical Trials and the Implications for Oncology Treatment Approaches
Emerging Role of Histone Deacetylase Inhibitors As Anti-Breast-Cancer
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri